最新ニュース Novavax (NASDAQ:NVAX) 株価情報

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Novavax Inc

NOVAVAX ORD

Novavax said it is aware of an analyst report published on October 1, 2024, which referred to discussions with Novavax&rsquo;s management regarding, among other things, the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season.&nbsp;

Novavax Clarifies That While It Has Anticipated COVID-19 Vaccination Market In US Will Be Similar To Last Year, It Has Neither Updated Nor Reaffirmed FY24 Financial Guidance Issued On August 8 - Filing

Jefferies analyst Roger Song maintains Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Buy and maintains $31 price target.

Price Target

Analyst Ratings

Jefferies Maintains Buy on Novavax, Maintains $31 Price Target

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has outperformed the market over the past 5 years by 10.54% on an annualized basis producing an average annual return of 25.09%. Currently, Novavax has a market capitalization of $2.32 billion. 
Buying $1000 In NVAX: If an investor had bought $1000 of NVAX stock 5 years ago, it would be worth $2,898.22 today based on a price of $14.52 for NVAX at the time of writing.
<h3>Novavax's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727894019_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Novavax 5 Years Ago Would Be Worth Today

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.2% on Wednesday.
Shares of RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) rose sharply during Monday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/RPM/earnings">first-quarter adjusted EPS results</a>.
Sales declined 2.1% Y/Y to $1.97 billion, missing the consensus of $2.015 billion. Adjusted EPS was $1.84, beating the consensus of $1.75.
RPM shares jumped 7.2% to $128.71 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 21.6% to $3.88.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) gained 20% to $7.46. Shares of US-listed Chinese stocks traded higher on continued strength following recent stimulus measures and the start of the National Day Golden Week.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) gained 19.4% to $5.73 after the company announced that Toyota will invest an additional $500 million to support the certification and commercial production of the electric air taxi.</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) climbed 17.1% to $3.7473.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 12% to $3.1113.</li>
<li>Talkspace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>) surged 12% to $2.3650.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) climbed 10.7% to $9.52.</li>
<li>Great Lakes Dredge &amp; Dock Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLDD#NASDAQ">GLDD</a>) climbed 9.7% to $11.76 after the company announced the receipt of several dredging awards totaling $342.3 million.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 9.3% to $13.47.</li>
<li>Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) rose 6.5% to $65.44. Ciena announced a $1 billion share repurchase authorization.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41141371/levi-strauss-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-">Levi Strauss Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Intraday Update

Markets

CIEN

CLOV

GLDD

JOBY

OKLO

TALK

TIGR

RPM International Posts Upbeat Earnings, Joins Joby Aviation, Ciena And Other Big Stocks Moving Higher On Wednesday

Biotech

Global

General

World Organization For Animal Health Says Hungary And Italy Report Farm Outbreaks Of Highly Pathogenic H5N1 Bird Flu

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 6.09% since its last report. The company recently reported that it has 33.53 million shares sold short, which is 26.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727789422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 13.61%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Novavax's Recent Short Interest

Macro Economic Events

Economics

World Organization For Animal Health Says Germany Reports Outbreak Of Highly Pathogenic H5N1 Bird Flu On Farm In Eastern Part Of The Country

<a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html" title="https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html">https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html</a>

Reported September 23; Health Canada Approves Novavax Nuvaxovid And XBB.1.5 Omicron Subvariant COVID-19 Vaccines For Primary And Booster Doses

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) has outperformed the market over the past 5 years by 1.97% on an annualized basis producing an average annual return of 15.62%. Currently, Novavax has a market capitalization of $2.14 billion. 
Buying $1000 In NVAX: If an investor had bought $1000 of NVAX stock 5 years ago, it would be worth $2,000.00 today based on a price of $13.38 for NVAX at the time of writing.
<h3>Novavax's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726581683_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Novavax 5 Years Ago Would Be Worth This Much Today

Florida Governor Ron DeSantis' administration has reportedly issued updated guidance recommending that healthcare providers steer vulnerable patients away from mRNA-based COVID-19 vaccines.
The Florida Health Department is raising concerns about the safety of the mRNA vaccines, pointing to potential risks such as myocarditis and postural orthostatic tachycardia syndrome (POTS), rare heart conditions. This stance contrasts sharply with recommendations from federal health agencies, which continue to endorse mRNA vaccines as safe and effective for all eligible individuals.
In June, the U.S. CDC recommended <a target="_blank" href="https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html" rel="noreferrer noopener">using</a> updated 2024-2025 COVID-19 vaccines in individuals six months and older.
The FDA in August <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514864/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-but-leaves-out-novavaxs-shot" rel="noreferrer noopener">granted emergency use</a> approval for updated mRNA-based COVID-19 vaccines from Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)/BioNTech SE's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), targeting the Omicron variant KP.2 strain.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40347291/long-covid-remains-diagnostic-mystery-diagnosis-remains-elusive-national-institutes-of-health-fun" rel="noreferrer noopener">Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows</a>.
The NBC News highlights that the state's health department is advising that individuals aged 65 and older, along with those with underlying health conditions, prioritize access to non-mRNA vaccines and treatments instead.
Earlier this month, the FDA granted Emergency Use Authorization to&nbsp;Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)&nbsp;protein-based COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40660946/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s" rel="noreferrer noopener">individuals aged 12 and older</a>.
The state's guidance emphasizes that high immunity levels from prior infections, combined with current data, justify their position.
The report <a target="_blank" href="https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997" rel="noreferrer noopener">adds</a> that while there is a documented small risk of myocarditis linked to the mRNA vaccines, especially in younger males, studies show most cases are mild and resolve fully.
Research published in Nature Cardiovascular Research highlights that individuals infected with COVID-19 are five times more likely to develop POTS than those vaccinated with mRNA vaccines, reinforcing the importance of vaccination.
Researchers from the Universities of Cambridge, Bristol, and Edinburgh revealed that COVID-19 vaccinations may significantly reduce the incidence of arterial thromboses, a leading cause of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40348867/struggling-covid-19-vaccines-from-astrazeneca-biontechpfizer-moderna-cut-incidence-of-arterial-th" rel="noreferrer noopener">heart attacks and strokes</a>.
Price Action: MRNA stock is up 2.37% to $69.90, PFE stock is up 2.12% to $29.89 at the last check on Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40875211/bhp-group-sounds-alarm-on-copper-supply-ai-and-ev-growth-could-drive-prices-soaring-report" target="_blank" rel="noreferrer noopener">BHP Group Sounds Alarm on Copper Supply, AI and EV Growth Could Drive Prices Soaring: Report</a>.</li>
</ul>
Image via Shutterstock

Government

Health Care

Legal

Media

BNTX

MRNA

DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions

<a href="https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997">https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997</a>
Even as the Covid wave in Florida continues, Gov. Ron DeSantis' administration is once again advising against the mRNA vaccines: this time in the most vulnerable residents.
In updated guidance for health care providers released Thursday, the Florida Health Department and state Surgeon General Joseph Ladapo questioned the safety and effectiveness of <a href="https://content.govdelivery.com/accounts/FLDOH/bulletins/3b56786">the mRNA Covid vaccines</a> from Pfizer and Moderna, including for older adults and people with underlying health problems. "Any provider concerned about the health risks associated with Covid-19 for patients over the age of 65 or with underlying health conditions should prioritize patient access to non-mRNA Covid-19 vaccines and treatment," according to the state guidance.
Standing in opposition to <a href="https://www.nbcnews.com/health/health-news/new-covid-vaccine-what-know-when-available-timing-rcna167121">advice from federal health agencies</a> and other medical experts about the safety of the Covid vaccines,&nbsp;the Florida Health Department said the recommendation was based on high rates of immunity from prior infections and "currently available data."
Without noting the <a href="https://www.cdc.gov/covid/risk-factors/index.html#:~:text=Older%20adults%20are%20at%20highest,people%20ages%2018%2D29%20years.">high risk of serious Covid infection or hospitalization for older adults</a>, the guidance listed safety concerns for the mRNA vaccines, including the risk of a rare heart condition called myocarditis, as well as the risk of <a href="https://www.nbcnews.com/health/health-news/pots-debilitating-heart-condition-linked-covid-lesser-degree-vaccines-rcna61226">POTS, or postural orthostatic tachycardia syndrome</a>, a debilitating heart condition.&nbsp;
Numerous studies have shown that both Pfizer and Moderna's vaccines are indeed associated with a small <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html">but increased risk of myocarditis</a>. However, most cases occur in young men and most people make a full recovery. Studies have also shown that the risk of myocarditis is much higher with a Covid infection and is often more severe than the vaccine-associated condition.
A study published <a href="https://www.nature.com/articles/s44161-022-00177-8">in Nature Cardiovascular Research</a>​ also found that people diagnosed with Covid are five times more likely to develop POTS after infection than after Covid vaccination, emphasizing the importance of the vaccine.
Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia, said the Florida surgeon general's guidance is unnecessarily alarming people about the Covid vaccines.
"It's just such a dangerous game he plays," said Offit, who has served on the FDA's independent vaccine advisory committee. "You only have a roughly 1,000 times greater likelihood of dying [from Covid] if you're over 65 than if you're under 18."
"The mRNA vaccines are remarkably safe," he added.
New doses of the Pfizer and Moderna vaccines were <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently">approved by the Food and Drug Administration</a> in August. They're targeted to the <a href="https://publichealth.jhu.edu/2024/what-to-know-about-covid-flirt-variants">KP.2 version of the steadily mutating virus </a>and should provide good protection against severe illness, hospitalization and death, experts say.&nbsp;
&nbsp;
The United States offers only one <a href="https://www.nbcnews.com/health/health-news/fda-authorizes-novavaxs-updated-covid-vaccine-targeting-jn1-strain-rcna169065">Covid vaccine that isn't mRNA-based: Novavax.</a> Novavax's traditional protein-based shot offers an alternative vaccine technology to mRNA. &nbsp;
In a statement, a Novavax spokesperson said its updated vaccine is now available at thousands of retail and pharmacy locations nationwide.
The Florida Health Department did not immediately respond to a request for additional comment.&nbsp;
Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto, called Florida's recommendation "unfortunate," saying it could put older adults and people with underlying health conditions at risk.
"While the vaccine does not protect against infection nearly as well as it once did, there is very good data demonstrating how Covid vaccines can reduce the risk of severe manifestations of the virus in those who are at greatest risk," said Boguch, who has no ties to the vaccine makers.&nbsp;
Covid cases remain high in the U.S. following a summer wave. Wastewater data collected between Aug. 25 and Aug. 31 shows that 23 states -- including Florida -- are reporting "very high" levels of the virus, <a href="https://www.cdc.gov/nwss/rv/COVID19-currentlevels.html">according to the CDC</a>. Emergency department visits and hospitalizations remain <a href="https://covid.cdc.gov/covid-data-tracker/#datatracker-home">elevated as well</a>, although they're showing signs of declining. In Florida nursing homes, after declining from summer highs, Covid infections are ticking up again, <a href="https://www.cdc.gov/nhsn/covid19/ltc-report-overview.html#anchor_1594393304">according to CDC data.&nbsp;</a>
&nbsp;
The CDC <a href="https://www.cdc.gov/media/releases/2024/s-t0627-vaccine-recommendations.html">currently recommends</a> everyone ages 6 months and older get an updated Covid vaccine this fall from any of the three options.&nbsp;
This isn't the first time Ladapo has ignored CDC guidance. Last year, Ladapo <a href="https://www.nbcnews.com/health/health-news/desantis-administration-advises-no-covid-shots-under-65-rcna104912">also recommended</a> that Florida residents under the age of 65 not get the mRNA Covid vaccines, citing widespread immunity and "questions we have about safety and about effectiveness."
"My judgment is that it's not a good decision for young people and for people who are not at high risk at this point in the pandemic," he said.&nbsp;

"Florida Discourages Use Of mRNA Covid Vaccines In Older Adults; In Updated Guidance To Health Care Providers, Florida Health Officials Advise That "Non-mRNA Covid-19 Vaccines And Treatment" Should Be Prioritized" - NBC News

WIIM

Novavax shares are trading higher after the company announced doses of its 2024-2025 Formula COVID-19 vaccine are now available at thousands of locations nationwide.

<ul>
<li>Doses of Novavax's 2024-2025 Formula COVID-19 vaccine now available at thousands of locations nationwide</li>
<li>Novavax's updated vaccine is the only protein-based option available in the U.S. this fall for individuals aged 12 and older</li>
</ul>

Does Of Novavax 2024-2025 Formula COVID-19 Vaccine Available Across U.S.

Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares are on watch Thursday. Here&#8217;s a recap of recent events. 
Key Developments:
<ul>
<li>Short Interest: Novavax's short interest has fallen, signaling that fewer investors are betting against the stock. It would take about 3.09 days to cover all short positions based on average trading volumes.</li>
<li>FDA Approval: Novavax's updated COVID-19 vaccine has been approved and will be available at thousands of locations across the U.S., including retail pharmacies and grocers. This approval strengthens Novavax's position in the market as it continues to offer a unique protein-based vaccine alternative.</li>
<li>Revenue Guidance: In August, Novavax lowered its 2024 revenue guidance to between $700 million and $800 million, significantly below earlier projections.</li>
</ul>
In comparison, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) also shared updates during its R&amp;D day, projecting 2025 revenues of $2.5 billion to $3.5 billion, below the consensus of $3.74 billion. The company is cutting its R&amp;D budget by $1.1 billion by 2027 and focusing on ten prioritized products. Despite lower-than-expected revenue forecasts, Moderna remains confident in its long-term growth and cash reserves.
NVAX Price Action: Novavax shares were down by 2.48% at $11.99 according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1722883001180099"><img loading="lazy" decoding="async" width="1024" height="550" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-1024x550.png" alt="" class="wp-image-544971" style="width:514px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-1024x550.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX-768x413.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12104437/NVAX.png 1074w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/40835602/jim-cramer-sees-opportunity-in-micron-stock-as-death-cross-earnings-approach">Jim Cramer Sees Opportunity In Micron Stock As Death Cross, Earnings Approach</a></li>
</ul>
Photo via Shutterstock.

Why Are Novavax Shares Trading Lower Today?

Novavax shares are trading lower. The stock may be down in sympathy with vaccine maker Moderna, which cut its R&D outlook.

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Sept. 6:
Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>): The technology giant is seeing strong interest from Benzinga readers ahead of Monday's first-quarter financial results. 
The company is expected to report earnings per share of $1.33, up from $1.19 in last year's first quarter, according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a> The company has beaten earnings per share estimates from analysts in seven straight quarters and eight of the past 10 quarters overall. 
Analysts estimate the company will report first-quarter revenue of $13.24 billion, up from $12.94 billion in last year's first quarter. The company has missed revenue estimates from analysts in four straight quarters and six of the past 10 quarters overall. 
Oracle <a href="https://www.benzinga.com/news/earnings/24/06/39280057/oracle-misses-q4-earnings-stock-surges-on-booming-ai-demand-openai-contract-partnership-with-google">highlighted AI demand</a> in the fourth quarter with more than 30 AI sales contracts valued at over $12.5 billion signed, including a large contract with OpenAI. Oracle also announced a partnership with Google Cloud at the time.
Oracle shares are up 2.3% over the last five days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1">Benzinga Pro chart </a>below. Oracle stock is up 38% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png" alt="" class="wp-image-534842" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105358/Screenshot-162-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>): Shares of the vaccine company were up over 4% in the past five days with news that the FDA granted Emergency Use Authorization of the company's<a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants"> updated COVID-19 vaccine</a>. The updated vaccine is included in the recommendations from the U.S. Centers for Disease Control and Prevention (CDC). 
The vaccine is the only protein-based option available in the U.S. for people aged 12 and older for the prevention of COVID-19. The company could also be drawing interest from investors ahead of two company presentations next week. Novavax will present at H.C. Wainwright and Baird investor conferences on Monday, Sept. 9 and Tuesday, Sept. 10, respectively.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="989" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png" alt="" class="wp-image-534844" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163.png 989w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105414/Screenshot-163-768x390.png 768w" sizes="(max-width: 989px) 100vw, 989px" /></a></figure>
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
Wheeler Real Estate Investment Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHLR#NASDAQ">WHLR</a>): Shares of the real estate investment trust surged over 500% on the week after the company <a href="https://ir.whlr.us/news-events/press-releases/detail/1088/cedar-realty-trust-and-wheeler-real-estate-investment-trust-announce-fourth-circuit-court-affirms-dismissal-of-class-action-lawsuit">announced </a>a circuit court affirmed the dismissal of a class action lawsuit involving holders of Cedar Realty preferred stock. Wheeler acquired Cedar in August 2022 and the lawsuit alleged a breach of contract related to Cedar's former board of directors.
"With this matter behind us, both companies remain well-positioned to execute on their strategic plans," Cedar and Wheeler CEO Andrew Franklin said.
The company owns 77 grocery-anchored shopping centers in the Northeast, Mid-Atlantic and Southeast covering 14 states. With the lawsuit behind the company, investors could see a positive long-term outlook.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png" alt="" class="wp-image-534845" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105430/Screenshot-164-768x388.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Equinix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): The data center company saw strong interest from investors on the week with shares up minimally. The company <a href="https://investor.equinix.com/news-events/press-releases/detail/1051/equinix-issues-more-than-750-million-in-green-bonds-to">announced </a>it issued $750 million in green bonds across two completed offerings. The green bonds are being used to help with sustainability initiatives for the company.
"Green bonds serve as a valuable means to secure funding and support significant initiatives that enhance the sustainability of our operations," Equinix SVP Corporate Finance and Sustainability Katrina Rymill said. "Over the last five years, our green bonds have funded 172 green building projects across 105 sites, 33 energy efficient projects and two Power Purchase Agreement projects."
The new green bonds could help the company continue to invest in new efforts to help support the company's 86 consecutive quarters of top-line revenue growth, which the company said is the longest streak of any S&amp;P 500 company.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png" alt="" class="wp-image-534850" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105452/Screenshot-165-768x387.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Tenon Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>): Investor interest in the medical device company grew during the week thanks to two <a href="https://ir.tenonmed.com/">items</a>. The company announced a 1:8 reverse stock split on Sept. 4 that took effect on Sept. 6. Reverse stock splits often draw attention from retail investors as they reduce the float and shares outstanding of a company. 
Tenon also announced a peer-reviewed publication of its Catamaran SI Joint Fusion System. The peer review showed evidence of fusion at the 12-month mark post-procedure, the company said.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="991" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png" alt="" class="wp-image-534851" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166.png 991w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06105510/Screenshot-166-768x389.png 768w" sizes="(max-width: 991px) 100vw, 991px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090624&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/08/40284758/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 9</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 16</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 23</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">August 30</a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40748240/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q1 Earnings</a></li>
</ul>

REIT

Stock Split

Exclusives

Tech

Real Estate

EQIX

ORCL

TNON

WHLR

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has fallen 17.52% since its last report. The company recently reported that it has 28.76 million shares sold short, which is 22.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.09 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725458423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 11.76%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Novavax?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).
Nikola shares dipped 10.4% to $7.28 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares jumped 103% to $0.6719. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 85% to $3.70.</li>
<li>SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) surged 65% to $2.3950 after the company announced it entered into a definitive agreement to be acquired by Highwire Capital for $2.50 per share.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) rose 62.7% to $2.31.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares jumped 56% to $1.0250 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) gained 44.6% to $1.25 after the company announced it recently launched both Apple CarPlay and Android Auto interfaces for its faidr mobile application.</li>
<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) surged 43.5% to $115.92 after the company announced it selected VAX-31 to advance to an adult Phase 3 program following topline results from its Phase 1/2 study.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 28.8% to $21.69.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 21.8% to $6.57 after the company received a favorable legal ruling from the U.S. ITC in its patent infringement complaint against Voltage, LLC and a related foreign entity.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) jumped 17.5% to $6.55 after the company announced it dosed 5 new patients in its ACHIEVE Phase 2b trial.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) rose 16.5% to $1.27.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 16% to $1.4150 after the company appointed former Stellantis executive Jean-Francois Mady as its new CFO.</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) surged 15.8% to $2.34.</li>
<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) gained 15.3% to $1.73. MediciNova recently announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 for post-COVID conditions.</li>
<li>GD Culture Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) rose 12.8% to $6.86.</li>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) jumped 12.6% to $5.99.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) gained 11.4% to $8.29.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) rose 11.3% to $1.3250.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) gained 10.7% to $12.57 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 9.4% to $17.91 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
<li>Intchains Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) climbed 8.1% to $7.89.</li>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) gained 8.1% to $49.04 after the company announced an update on enrollment in the Phase 2 TROPOS trial.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 4.5% to $12.94. Friday, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares dipped 42.2% to $4.68.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) fell 31.7% to $31.47. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 31.3% to $1.75 after jumping 60% on Friday.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) dipped 29.3% to $1.06 after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) fell 25.8% to $1.1499. Brenmiller recently reported a year-over-year increase in H1 EPS results. Also, the company announced a projected pipeline valued up to $500 million.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) dipped 22.8% to $1.13.</li>
<li>Four Seasons Education (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEDU#NYSE">FEDU</a>) fell 21.8% to $13.30.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) declined 21.6% to $3.55.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 18.8% to $1.5506.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) dipped 18.6% to $3.99.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 16.1% to $8.49.</li>
<li>LightInTheBox Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NASDAQ">LITB</a>) declined 14.3% to $0.4455.</li>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) fell 12.7% to $16.97 as the company announced planned CEO transition.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) fell 10.8% to $4.2350.</li>
<li>Nova Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) declined 9.6% to $202.16.</li>
<li>Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) fell 8.5% to $81.15.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) fell 8.5% to $109.35.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 8.3% to $159.27 ahead of the September 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) dipped 8% to $75.43.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) fell 7.2% to $70.73.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) declined 7% to $20.52.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 6.2% to $185.01.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were lower, with the Nasdaq Composite falling around 2% on Tuesday.
Shares of Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) rose sharply during Tuesday's session after the company released topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the company&#8217;s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent <a href="https://www.benzinga.com/general/biotech/24/09/40688264/bacterial-infections-vaccine-developer-vaxcytes-pneumococcal-shot-shows-promise-in-mid-stage-tria">invasive pneumococcal disease.</a>
VAX-31 was well tolerated and demonstrated a safety profile at all doses studied through the full six-month evaluation period, similar to Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Prevnar 20 (PCV20).
Vaxcyte shares jumped 43.5% to $115.92 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) shares rose 28.8% to $21.69.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) gained 21.8% to $6.57 after the company received a favorable legal ruling from the U.S. ITC in its patent infringement complaint against Voltage, LLC and a related foreign entity.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) rose 16% to $1.4150 after the company appointed former Stellantis executive Jean-Francois Mady as its new CFO.</li>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) gained 12.6% to $5.99.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) jumped 10.7% to $12.57 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) rose 9.4% to $17.91 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
<li>BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) jumped 8.5% to $30.24. HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterated BridgeBio Pharma with a Buy and maintained a $43 price target.</li>
<li>Montana Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) gained 8.4% to $6.05.</li>
<li>Intchains Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) gained 8.1% to $7.89.</li>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) climbed 8.1% to $49.04 after the company announced an update on enrollment in the Phase 2 TROPOS trial.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) rose 4.8% to $8.44. XPeng delivered 14K smart EVs in August, up by 3% year over year.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) gained 4.5% to $39.53. JP Morgan analyst Anupam Rama maintained Vera Therapeutics with an Overweight and raised the price target from $62 to $72.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose 4.5% to $12.94. Friday, the FDA granted Emergency Use Authorization to the company's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) gained 3.7% to $14.91. B of A Securities analyst Brad Sills maintained Bilibili with a Buy and raised the price target from $18 to $19.</li>
<li>The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) rose 3.1% to $118.27.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

AIRJ

BBIO

BILI

VERA

XPEV

Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday

Friday, the FDA granted Emergency Use Authorization to Novavax Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40660946/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s" rel="noreferrer noopener">individuals aged 12 and older</a>.
Novavax&#8217;s vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on&nbsp;June 27, 2024.
Following the Center for Biologics Evaluation and Research&#8217;s release of vaccine batches, pre-filled syringes of the vaccine will be available in thousands of locations, including retail and independent pharmacies and regional grocers.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40514864/fda-approves-updated-covid-vaccines-from-pfizer-and-moderna-but-leaves-out-novavaxs-shot" rel="noreferrer noopener">FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax&#8217;s Shot</a>.
&#8220;Our updated vaccine targets JN.1, the &#8216;parent strain&#8217; of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1,&#8221; said John C. Jacobs, President and Chief Executive Officer, Novavax.
In June, the CDC&#8217;s Advisory Committee on Immunization Practices voted unanimously in favor of a universal recommendation for the use of 2024-2025 COVID-19 vaccines authorized under EUA or approved by Biologics License Application in individuals aged six months and older, regardless of specific viral strains.
The approval was based on non-clinical data that showed Novavax&#8217;s updated vaccine provides protection and cross-reactivity against JN.1 and numerous JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1, and LB.1.
Novavax says its vaccine&nbsp;is the only protein-based option available in the U.S. for individuals aged 12 and older to prevent COVID-19.
Doses are on track to be available as early as the end of next week, the company said in an email to Reuters.
In August, Novavax lowered its 2024 revenue guidance to $700 million – $800 million, including revenue recognition of Sanofi Payment, compared to the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40260847/covid-19-vaccine-maker-novavax-trims-annual-outlook-as-q2-sales-take-a-hit" rel="noreferrer noopener">consensus of $936.38 million</a>.
Earlier, the company expected sales of $970 million – $1.17 billion in combined revenue and Sanofi agreement payment.
Price Action: NVAX stock is up 3.30% at $12.79&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40659011/johnson-johnson-spin-off-kenvue-wins-lawsuit-over-pain-killer-tylenol-rapid-release-gelcaps" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol &#8216;Rapid Release&#8217; Gelcaps</a>.</li>
</ul>
Photo via Shutterstock

FDA Approves Novavax's Updated COVID Vaccine Targeting Currently Circulating Variants

Novavax, Inc. (NVAX) H.C. Wainwright 26th Annual Global Investment Conference (Transcript)

Novavax, Inc. (NVAX) Baird 2024 Global Healthcare Conference (Transcript)

Novavax COVID-19 vaccines now available

Moderna's Move Shows Lack Of Confidence, Shrinks Pipeline

Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.

Biotech Stocks : Are You A Trader Or A Longer Term Investor?

In a report released today, Roger Song from Jefferies maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of $31.00. T...

Jefferies Sticks to Their Buy Rating for Novavax (NVAX)

Novavax stock rallies 15% following bullish Jefferies note

Novavax ( ($NVAX) ) has provided an update. Novavax, Inc. has acknowledged a recent analyst report discussing the expected U.S. COVID-19 vaccine ma...

Novavax Comments on Expected U.S. Vaccine Market Outlook

Novavax cools after clarifying analyst report on COVID vaccine market

Novavax: Lack Of Sustainable Revenue Growth Is A Problem

ARGX

CRMD

IMTX

Press Releases

Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

Earnings

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

Novavax to Participate in Upcoming September Conferences

Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

Comments

Novavax

ニュース

最新ニュース Novavax (NASDAQ:NVAX) 株価情報

月曜日, 6 10, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル